As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal
Two Assets Outlicensed
The outlicensing deal will free up MorphoSys' internal resources to focus on key pipeline assets, starting with pelabresib. • Source: Shutterstock 
